文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

口服靶向抗癌药依从性对药动/药效关系的影响

Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

本文讨论口服靶向抗癌药长期治疗中依从性不佳的问题,指出多数药物按标准非个体化剂量给药,个体间变异大,依从性差可导致血药浓度过高或过低。以伊马替尼为代表的研究显示,未报告的依从性不足会干扰治疗药物监测(TDM)的浓度解读和剂量调整,也可能偏倚药动学模型及贝叶斯TDM。目前肿瘤领域尚缺乏依从性对血药浓度影响的详细数据,亟需相关研究及依从性管理项目。

要点

  • 口服靶向抗癌药长期依从性可能不佳,影响临床结局。
  • 未报告的依从性不足可偏倚TDM浓度解读与剂量调整。
  • 依从性数据缺失也可能影响药动学模型及贝叶斯TDM。

核心结论

  • 口服靶向抗癌药依从性不佳可导致血药浓度过高或过低,进而影响疗效与毒性。
  • 未报告的依从性不足会干扰TDM浓度解读、剂量调整及药动学模型结果。
  • 肿瘤领域亟需开展依从性对血药浓度影响的研究并建立有效依从性管理项目。

研究设计与样本

  • 本文为综述,围绕口服靶向抗癌药依从性与药动/药效关系进行论述。

主要发现

  • 多数口服靶向抗癌药按标准非个体化剂量给药,个体间变异显著。
  • 以伊马替尼为代表的研究已关注依从性对临床结局的影响。
  • 依从性不足可能导致TDM浓度解读偏倚和不恰当的剂量调整。
  • 依从性数据缺失可偏倚药动学建模,进而影响贝叶斯TDM解读。

临床怎么用

  • 在TDM解读和剂量调整时应主动评估并记录患者依从性。
  • 开展药动学建模和贝叶斯TDM时应考虑依从性数据的完整性。

局限性

  • 肿瘤领域目前缺乏依从性对血药浓度影响的详细知识。
  • 相关研究尚待开展,有效依从性管理项目仍需开发与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The emergence of oral targeted anticancer agents transformed several cancers into chronic conditions with a need for long-term oral treatment. Although cancer is a life-threatening condition, oncology medication adherence-the extent to which a patient follows the drug regimen that is intended by the prescriber-can be suboptimal in the long term, as in any other chronic disease. Poor adherence can impact negatively on clinical outcomes, notably because most of these drugs are given as a standard non-individualized dosage despite marked inter-individual variabilities that can lead to toxic or inefficacious drug concentrations. This has been especially studied with the prototypal drug imatinib. In the context of therapeutic drug monitoring (TDM), increasingly advocated for oral anticancer treatment optimization, unreported suboptimal adherence affecting drug intake history may lead to significant bias in the concentration interpretation and inappropriate dosage adjustments. In the same way, suboptimal adherence may also bias the results of pharmacokinetic modeling studies, which will affect in turn Bayesian TDM interpretation that relies on such population models. Detailed knowledge of the influence of adherence on plasma concentrations in pharmacokinetic studies or in routine TDM programs is however presently missing in the oncology field. Studies on this topic are therefore eagerly awaited to better pilot the treatment of cancer with the new targeted agents and to find their optimal dosage regimen. Hence, the development and assessment of effective medication adherence programs are warranted for these treatments.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cardoso E, Csajka C, Schneider MP, et al. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clin Pharmacokinet. 2018. PMID: 28634655. doi:10.1007/s40262-017-0571-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。